Rapid Reviews in Hematology™: Updates from San Diego on Therapeutic Advancements in Hemolytic Anemias – A Focus on Paroxysmal Nocturnal Hemoglobinuria

Released On
February 18, 2021

Expires On
February 18, 2022

Media Type

Completion Time
90 minutes


Bleeding Disorders

Scroll to the Bottom of this Information to Begin this Course

This activity is jointly provided by Physicians’ Education Resource®, LLC.

This activity is supported by an educational grant from Apellis Pharmaceuticals, Inc.

Credit Available

  • Physicians — maximum of 1.50 AMA PRA Category 1 Credit(s)
  • Nurses — 1.50 Contact Hours

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

These activities are intended for hematologists, oncologists, and other health care professionals interested in understanding the treatment guidelines and strategies for managing patients with hemolytic anemias. Fellows, researchers, nurses, nurse practitioners, physician assistants, and other health care professionals are also invited to attend.

Activity Overview

Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired blood disorder characterized by hemolytic anemia, thrombosis, and impaired bone marrow function. Given its spectrum of disease, PNH is associated with significant disease burden. Importantly, there have been ongoing advances related to current and emerging therapeutic options for its management that offer significant promise.

This online, on-demand virtual symposium features a panel discussion among hematology experts, highlighting the implications and applications of data regarding the treatment and management of PNH. The panel discusses topics that include the efficacy and safety of available and investigational therapies, strategies for treatment planning, and quality of life aspects for affected patients.

This educational activity is an archive of the live virtual symposium held on January 28, 2021.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Relate the pathophysiology of PNH to targets for its management
  • Examine emerging clinical trial evidence regarding current and emerging therapies for patients with PNH
  • Develop patient-centric treatment plans for patients with PNH



Craig M. Kessler, MD, MACP

Professor of Medicine and Pathology
Director, Division of Coagulation
Lombardi Comprehensive Cancer Center
Georgetown University Medical Center
Washington, DC


Robert A. Brodsky, MD

The Johns Hopkins Family Professor of Medicine and Oncology
Director, Division of Hematology
Director, Physician-Scientist Pathway Osler Medical Program
Johns Hopkins University School of Medicine
Baltimore, MD


Catherine Broome, MD

Associate Professor of Medicine
Georgetown University
Lombardi Comprehensive Cancer Center
Washington, DC


Ilene Ceil Weitz, MD

Professor of Clinical Medicine
Jane Anne Nohl Division of Hematology
Keck School of Medicine
University of Southern California
Los Angeles, CA

Accreditation/Credit Statement

Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.50 Contact Hours.

Disclosures of Conflicts of Interest

Craig M. Kessler, MD, MACP

  • Grant/Research Support: Octapharma, Takeda Pharmaceutical Company
  • Consultant: CSL Behring, Octapharma, Takeda Pharmaceutical Company
  • Other Support: Director, 340B Program at Hemophilia Treatment Centers, Novartis Pharmaceuticals, Rigel Pharmaceuticals

Robert A. Brodsky, MD

  • Consultant:: Alexion Pharmaceuticals

Catherine Broome, MD

  • Consultant: Alexion Pharmaceuticals, Apellis Pharmaceuticals, Argenx, Sanofi

Ilene Ceil Weitz, MD

  • Consultant: Alexion Pharmaceuticals, Apellis Pharmaceuticals
  • Speakers’ Bureau: Alexion Pharmaceuticals, Apellis Pharmaceuticals

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities.

Instructions for Participation and Credit

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.
You may immediately download your certificate.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.